GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
0
c/survodutide·posted 5 days ago by u/whois_wanda

glucagon co-agonism has its own safety story, stop generalising from tirz

Discussion Clean Column ×3

Confession thread, sort of.

I went from 2.4mg to 0.5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 5 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway.

So now I have sulphur burps I did not need and a data point I cannot interpret. Two lessons in one.

Posting it in the hope that somebody at week 23 reads it before doing the same thing.

0 up / 0 down41% upvoted9 commentsid 1au4et25 Jul 2026

9 comments

9 in this archive, depth 4

best — the order this archive was captured in

u/sofia_ferreira3 points·4 days ago

not approved, descriptive posts only

replysharereportpermalink
[deleted]2 points·3 days ago

[deleted]

replysharereportpermalink
u/whois_wandaOP1 point·3 days ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink
u/tuva_kirchner1 point·3 days ago·edited

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
u/andres_dahlberg1 point·3 days ago

not approved, descriptive posts only

replysharereportpermalink
u/julia_mensa2 points·3 days ago

hepatic fat and MASH are the story

replysharereportpermalink
u/hana_lehtinen2 points·2 days ago

hepatic fat and MASH are the story

Adding to this: hepatic fat is doing more work than the comment implies.

replysharereportpermalink
u/whois_wandaOP2 points·3 days ago

Came off after 34 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.

replysharereportpermalink
u/sofia_ferreira1 point·3 days ago

Hepatic fat or MASH or what?

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →